protocolSection identificationModule nctId: NCT06287398, orgStudyIdInfo id: NHL38, briefTitle: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2031-11, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Australasian Leukaemia and Lymphoma Group, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate clinical efficacy of incorporating Epcoritamab into the salvage treatment routine for relapsed-refractory aggressive B-cell lymphoma, followed by autologous stem-cell transplantation (ASCT) and consolidation Epcoritamab. The main questions it aims to answer are:* Will the addition of epcoritamab to intensive salvage chemotherapy be safe and increase the proportion of patients with relapsed or refractory (R/R) large B-cell lymphoma who achieve a complete remission prior to planned transplant?* Is consolidation epcoritamab after ASCT deliverable and safe?* Will consolidation epcoritamab will result in improved clearance of molecularly detectable residual disease?* Will the combination of pre- and post-ASCT epcoritamab lead to higher rates of progression-free survival (PFS) and event free survival (EFS) at 12 months compared to historical estimates in this population.Participants will undergo three phases in this trial:1. Epcoritamab-Salvage treatment: consists of 3 cycles of R-DHAOx (rituximab, dexamethasone, cytarabine, oxaliplatin) plus Epcoritamab2. ASCT: Pre-autograft eligibility assessment for ASCT will be performed according to local practice. ASCT may be administered at local referring centre and will follow local standard operative procedures.3. Consolidation treatment: consists of six 28-day cycles of subcutaneous Epcoritamab, commencing 6 - 12 weeks post ASCT., conditionsModule conditions: DLBCL - Diffuse Large B Cell Lymphoma, conditions: High-grade B-cell Lymphoma, conditions: High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, conditions: DLBCL, Nos Genetic Subtypes, conditions: High Grade B-Cell Lymphoma, Not Otherwise Specified, conditions: Follicular Large Cell Lymphoma, Relapsed, conditions: Follicular Large Cell Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ESTIMATED, armsInterventionsModule interventions name: Epcoritamab, outcomesModule primaryOutcomes measure: Event-free survival (EFS), secondaryOutcomes measure: Evaluate safety and tolerability of combination Epcoritamab with salvage-ASCT, secondaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Complete response rate (CRR), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Progression free survival (PFS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False